Processa Pharmaceuticals, Inc. has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $7,000,000.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Processa Pharmaceuticals, Inc. is raising $7,000,000.00 in new funding. About Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.
To learn more about Processa Pharmaceuticals, Inc., visit http://www.processapharmaceuticals.com/
Contact:
George Ng, Chief Executive Officer
443-776-3133
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.